<DOC>
	<DOCNO>NCT00052572</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : Phase II trial study effectiveness ixabepilone treat patient relapsed refractory lymphoproliferative disorder .</brief_summary>
	<brief_title>Ixabepilone Treating Patients With Relapsed Refractory Lymphoproliferative Disorders</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine frequency duration complete partial response rate patient relapse refractory indolent lymphoproliferative disorder treat ixabepilone . Secondary - Determine time progression overall survival patient treated drug . - Determine toxicity drug patient . OUTLINE : This open-label study . Patients receive ixabepilone IV 1 hour weekly 3 week . Courses repeat every 4 week absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 35 patient accrue study within 1-1.5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm relapsed/recurrent refractory indolent lymphoproliferative disorder 1 follow type : Chronic lymphocytic leukemia Absolute lymphocytosis great 5,000/mm^3 Bcell phenotype ( CD 19 , 20 , 23 positive ) 30 % bone marrow lymphocytes Bcell small lymphocytic lymphoma Marginal zone Bcell lymphoma Grade IIII follicle center cell lymphoma Waldenstrom 's macroglobulinemia Mantle cell lymphoma At least 1 unidimensionally measurable lesion patient nonHodgkin 's lymphoma At least 2 cm conventional technique No active brain metastasis Treated CNS disease allow PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 60100 % Life expectancy At least 3 month Hematopoietic Absolute neutrophil count ≥ 1,000/mm^3 ( 500/mm^3 lymphomatous involvement bone marrow ) Platelet count ≥ 50,000/mm^3 Hepatic Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 2.5 time ULN ( 4 time ULN liver involvement ) Renal Creatinine ≤ 2 time ULN OR Creatinine clearance ≥ 50 mL/min Cardiovascular No history orthostatic hypotension No myocardial infarction , cerebrovascular accident , transient ischemic attack within past 3 month No New York Heart Association class III IV congestive heart failure No unstable angina pectoris No cardiac arrhythmia No uncontrolled hypertension require manipulation antihypertensive medication No evidence follow echocardiogram : Acute ischemia Significant conduction abnormality Bifascicular block 2^nd 3^rddegree atrioventricular block Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No immunodeficiency No known severe hypersensitivity reaction agent contain Cremophor EL No ongoing active infection Febrile episodes 38.5° Celsius allow absence infection No concurrent uncontrolled illness would preclude study participation No psychiatric illness social situation would preclude study compliance No preexisting grade II great sensory neuropathy PRIOR CONCURRENT THERAPY : Biologic therapy At least 3 month since prior monoclonal antibody ( unless clearly document evidence disease progression therapy ) At least 3 month since prior radioimmunotherapy No prior allogeneic bone marrow transplantation Chemotherapy At least 4 week since prior cytotoxic chemotherapy ( 6 week mitomycin , nitrosoureas , carmustine ) recover No 4 prior chemotherapy regimen ( include highdose chemotherapy [ HDC ] patient relapse disease &gt; 100 day completion HDC ) Cytoreduction plus HDC consider 1 chemotherapy regimen No concurrent chemotherapy Endocrine therapy At least 7 day since prior steroid Radiotherapy More 3 week since prior radiotherapy recover No concurrent radiotherapy Surgery More 4 week since prior major surgery Other Use antibiotic marginal zone lymphoma count prior therapy No concurrent investigational agent No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2006</verification_date>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>Waldenström macroglobulinemia</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>